KIDNEY CANCER FOLLOW UP

RCC Risk & Follow-Up Planner

RCC Risk & Follow-Up Planner

Choose EAU 2026 or AUA/NCCN + Leibovich below, then estimate post-nephrectomy risk and view a risk-adapted surveillance schedule for renal cell carcinoma (RCC).

Produced by Dr. Mohit Sharma, UROWALA

EAU 2026 Guideline
AUA / NCCN + Leibovich 2018

EAU 2026 risk & follow-up

EAU 2026
Uses the exact risk models and surveillance table named in the EAU Guidelines on Renal Cell Carcinoma 2026 (Prognostic Factors & Follow-up chapters, uroweb.org). Shown by default below. Switch the toggle above to view the separate AUA/NCCN + 2018 Leibovich planner instead — the two are independent models and may give different results.
ccRCC — Leibovich 2003
Non-ccRCC (pT/grade)
Papillary — VENUSS

2003 Leibovich score — the model the EAU panel recommends (weak) for risk-of-recurrence stratification of localised/locally advanced ccRCC, distinct from the 9‑variable 2018 model used above.

Applies to papillary, chromophobe and other non-clear-cell histologies, per the pT/pN/grade criteria in EAU Table 9.1. For papillary RCC specifically, the panel separately endorses the VENUSS score (next tab) as a validated alternative.

VENUSS = Venous involvement, Necrosis, Size, Stage, Sarcomatoid differentiation — the EAU panel's recommended (weak) model specifically for papillary RCC risk-of-recurrence stratification.

EAU 2026 proposed follow-up schedule (Table 9.1)

Low risk Intermediate risk High risk
Risk3mo6mo12mo18mo24mo30mo36mo>3yr>5yr
Low–CT–CT–CT–CT / 2yr–*
Intermediate–CTCT–CT–CTCT / yrCT / 2yr**
HighCTCTCTCTCT–CTCT / yrCT / 2yr
  • CT = chest + abdomen CT at each listed time point after surgery; abdominal MRI may substitute for abdominal CT.
  • *Low risk, >3 years, and **intermediate risk, >5 years: the panel suggests counselling the patient on stopping oncological follow-up imaging, based on comorbidities, age, life expectancy and patient wishes.
  • Intensify follow-up after nephron-sparing surgery with a positive surgical margin (weak recommendation).
  • Consider curtailing follow-up once the risk of dying from other causes is roughly double the risk of RCC recurrence (weak recommendation).
  • Functional follow-up (renal function, cardiovascular risk) continues per clinical need regardless of oncological follow-up duration.
  • Routine PET-CT and bone scintigraphy are not recommended; targeted imaging (e.g. brain MRI) only for organ-specific symptoms.
  • The panel suggests offering psychological evaluation to all patients diagnosed with RCC, and nephrology referral for pre-existing/treatment-induced CKD or risk factors for renal function deterioration.

Source: EAU Guidelines on Renal Cell Carcinoma 2026 — Chapter 6 (Prognostic Factors) and Chapter 9 (Follow-up in RCC), uroweb.org/guidelines/renal-cell-carcinoma. Reproduced here for education; verify against the current full-text guideline before clinical use.

Produced by Dr. Mohit Sharma, UROWALA
Planner above (2018 model): built to mirror the structure of the 2018 Leibovich model (Leibovich BC, Lohse CM, Cheville JC, et al. Predicting Oncologic Outcomes in Renal Cell Carcinoma after Surgery. Eur Urol. 2018;73:772–780), with an AUA/NCCN-style surveillance schedule. Point weights for clear-cell RCC reflect the published progression-free-survival variables; papillary/chromophobe groupings are simplified approximations.

EAU 2026 section above: uses the 2003 Leibovich score, the EAU Table 9.1 pT/pN/grade criteria for non-ccRCC, the VENUSS score for papillary RCC, and the EAU Table 9.1 follow-up schedule, as published in the EAU Guidelines on Renal Cell Carcinoma 2026 (uroweb.org/guidelines/renal-cell-carcinoma). The two sections are intentionally separate models and may not agree on a given patient's risk tier.

Neither section is a validated substitute for the original publications, MDCalc, or the current full-text EAU guideline, and neither should replace clinical judgment, multidisciplinary input, or patient-specific decision-making.

Jaipur’s dedicated urology centre, built around the expertise of Dr. Mohit Sharma, an AIIMS-trained Urologist providing cutting-edge laser and surgical care.

Newsletter

Dr Mohit Sharma Urology AIIMS (Urowala)

21, GP Colony, Sumer Nagar, Mansarovar, Jaipur, Rajasthan 302020

Contact Us

+91 91835 70761

© 2026 Urowala Clinic. Designed By JusTech Creations